Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Endocrinology, Diabetes And Metabolism

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.6095